Front Page News
Cure SMA Newborn Screening Registry (NBSR)
In 2018, Spinal Muscular Atrophy (SMA) was added to the federal Recommended Uniform Screening Panel (RUSP), a panel of diseases that newborns in the United […]
Read More ›Zolgensma Update and Approval Webinars Now Available Online
A recording of last week’s webinar on Zolgensma updates is now available on Cure SMA’s YouTube channel. A presentation of the webinar can be found […]
Read More ›2019 Researcher Meeting Summary: Clinical Research Studies for SMA
The annual SMA Researcher Meeting is the largest research meeting in the world specifically focused on SMA. This year, we had a record setting 735 […]
Read More ›Team Cure SMA Completes the 2019 Falmouth Road Race in Cape Cod
Twenty Team Cure SMA runners completed the 2019 Falmouth Road Race on Sunday, August 18. Together, the runners successfully raised over $52,000 for Cure SMA, […]
Read More ›2019 SMA Researcher Meeting Summary: Basic Research Podium Presentations
The annual SMA Researcher Meeting is the largest research meeting in the world specifically focused on SMA. This year, we had a record setting 735 […]
Read More ›Thank You for a Wonderful 2019 Annual SMA Conference!
Thank you to everyone who attended the 2019 Annual SMA Conference at the Disneyland in Anaheim, California! It was an impactful weekend of community, research […]
Read More ›Cure SMA Awards Grants to Four States to Expediate the Implementation of SMA Newborn Screening
On July 3, 2018, Health and Human Services Secretary Alex Azar approved the recommendation that newborn screening for spinal muscular atrophy be implemented nationwide. This recommendation was […]
Read More ›2019 SMA Researcher Meeting Summary: Special Session on Spinal and Neuromuscular Circuitry: Exploring Defects in SMA and Potential Therapeutic Targets
The annual SMA Researcher Meeting is the largest research meeting in the world specifically focused on SMA. This year, we had a record setting 735 […]
Read More ›Cure SMA Update on Data Accuracy Issues with AveXis’ SMA Therapy, Zolgensma
Earlier this week, the FDA issued a statement identifying data accuracy issues with AveXis’ SMA therapy, Zolgensma. Cure SMA immediately opened an investigation into the […]
Read More ›Cure SMA Releases Status Update on Data Accuracy Issues with Zolgensma
Yesterday, the FDA issued a statement identifying data accuracy issues with Avexis’ SMA therapy, Zolgensma. Cure SMA is in communication with the FDA and is committed to […]
Read More ›